Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2203 Target Snapshot

Motilin receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,536Compounds
71Assays
3Approved Drugs
374.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Motilin receptor shows clinical signal disease relevance led by gastroparesis. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O43193. Start with gastroparesis, then reuse UniProt O43193 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with gastroparesis, then reuse UniProt O43193 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
gastroparesis

Motilin receptor shows clinical signal disease relevance led by gastroparesis. 2 linked drugs remain visible in the same block.

Start review with gastroparesis because it currently carries clinical signal support. Linked drugs include CAMICINAL, MITEMCINAL FUMARATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Motilin receptor as ChEMBL target CHEMBL2203, mapped to UniProt O43193. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Motilin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2203
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O43193
Motilin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Motilin receptor is the right protein anchor across sources, using UniProt O43193 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why gastroparesis is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMotilin receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtO43193
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMotilin receptor
UniProt AccessionO43193
Component TypeProtein
Sequence Length412 aa

Motilin receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Motilin receptor, mapped to UniProt O43193. Sequence length is 412 aa.

Mapped IDO43193
Review nameMotilin receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Motilin receptor shows clinical signal disease relevance led by gastroparesis.

Clinical signal Phase II
gastroparesis
2 linked drugs · 2 direct · 2 efficacy
Linked drugCAMICINAL
Linked drugMITEMCINAL FUMARATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with gastroparesis because it currently carries clinical signal support. Linked drugs include CAMICINAL, MITEMCINAL FUMARATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasegastroparesis
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC5035.0
KI104.0
EC50235.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL525634 10.4 EC50 0.03981 Preclinical
CHEMBL297494 10.33 EC50 0.047 Preclinical
CHEMBL2372767 9.82 EC50 0.15 Preclinical
CHEMBL296748 9.66 EC50 0.22 Preclinical
CHEMBL2364292 9.6 EC50 0.2512 Preclinical
CHEMBL2364312 9.6 EC50 0.2512 Preclinical
CHEMBL2364317 9.5 EC50 0.3162 Preclinical
CHEMBL2372767 9.44 Ki 0.36 Preclinical
CHEMBL2364285 9.4 EC50 0.3981 Preclinical
CHEMBL2364318 9.4 EC50 0.3981 Preclinical
Distribution

pChEMBL Value Distribution

16
5.0
26
5.5
36
6.0
24
6.5
53
7.0
50
7.5
62
8.0
35
8.5
12
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

ERYTHROMYCIN
CHEMBL532
Approved 1964
Properties Compare Identifier
Assay Landscape

Assay Landscape

71
Total Assays
209
Tested Compounds
2
Assay Types
Binding — 51 assays, 88 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 45 55 6.8
cell-based format 6 33 7.2
Functional — 20 assays, 209 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 15 201 7.6
assay format 3 8 7.8
single protein format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine